Linagliptin–-A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
Open Access
- 11 January 2012
- journal article
- Published by SAGE Publications in Clinical Medicine Insights: Endocrinology and Diabetes
- Vol. 5, CMED.S7274-11
Abstract
Incretin based therapies have been introduced into the treatment options of type 2 diabetes a few years ago. Among them, the orally active DPP-4 inhibitors have established themselves as insulinotropic agents. Their advantage is the glucose-dependent insulinotropic action without an intrinsic risk for causing hypoglycemia. Additionally DPP-4 inhibitors have a glucose dependent glucagonostatic action contributing to improved glucose control. They are weight neutral and show a good safety and tolerability profile with comparable efficacy to sulfonylureas. Linagliptin is a novel DPP-4 inhibitor with a distinct pharmacological profile. In contrast to the other approved DPP-4 inhibitors it is eliminated by a hepatic/biliary route rather than a renal route. Therefore no dose adjustment is recommended in patients with type 2 diabetes and renal impairment. In clinical studies, it has been shown to be non-inferior to sulfonylurea treatment regarding glycemic parameters, but to possess favourable safety advantages regarding hypoglycemia frequency, body weight development and effects on cardioavascular parameters. This article gives an overview on the pharmacology of linagliptin as well as on the clinical data available.Keywords
This publication has 36 references indexed in Scilit:
- Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2012
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programmeCardiovascular Diabetology, 2012
- Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes PatientsClinical Therapeutics, 2011
- Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled studyDiabetes, Obesity and Metabolism, 2010
- Enhanced Energy Expenditure, Glucose Utilization, and Insulin Sensitivity in VAMP8 Null MiceDiabetes, 2010
- Naloxone, but Not Valsartan, Preserves Responses to Hypoglycemia After Antecedent HypoglycemiaDiabetes, 2010
- Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placeboTrials, 2009
- 3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: A class of potent DPP-4 inhibitorsBioorganic & Medicinal Chemistry Letters, 2008
- The Absolute Oral Bioavailability and??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy VolunteersClinical Pharmacokinetics, 2007
- Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumEuropean Journal of Biochemistry, 1993